P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patientsECCO'22Year: 2022
Authors: Hubert, A.(1);Bottieau, J.(1);Toubeau, J.F.(1);Franchimont, D.(2,3);Vallée, F.(1);Liefferinckx, C.(2,3);
(1)University of Mons, Department of Electrical Engineering, Mons, Belgium;(2)Hôpital Erasme, Department of Gastroenterology, Brussels, Belgium;(3)Université libre de Bruxelles, Laboratory of experimental gastroenterology, Brussels, Belgium;
P387: Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) ProgramECCO'22Year: 2022
Authors: Komeylian, H.(1);Stewart, M.(1);Currie, B.(2);Phalen-Kelly, K.(2);Heisler, C.G.(2);Jones, J.(1);
(1)Dalhousie University, Medicine- Gastroenterology, Halifax, Canada;(2)Nova Scotia Health, Division of Digestive Care & Endoscopy, Halifax, Canada;
P389: Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United KingdomECCO'22Year: 2022
Authors: Lindsay, J.(1);Picker, N.(2);Kromer, D.(2);Smyth, M.(3);Patel, H.(4);
(1)Barts and the London School of Medicine- Queen Mary University of London, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(2)Ingress Health HWM, GmbH, Wismar, Germany;(3)Galapagos, Uk, Cambridge, United Kingdom;(4)Galapagos, Nv, Mechelen, Belgium;
P390: Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and NavarreECCO'22Year: 2022
Authors: Elorza, A.(1);Arzallus, T.(2);Izagirre, A.(2);Vicuña, M.(3);Rodriguez, C.(3);Cabriada, J.L.(1);Rodriguez-Lago, I.(1);
(1)Hospital Universitario de Galdakao, Gastroenterology, Galdakao, Spain;(2)Hospital Universitario de Donosti, Gastroenterology, Donosti, Spain;(3)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain;
P391: Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacyECCO'22Year: 2022
Authors: Carmody , E.(1);Haskett , J.(1);Parkinson-McGraw , L.(1);Grover , Z.(1);Martinez , A.(1);Rashid , M.(1);Otley MD MSc FRCPC, A.(1);
(1)IWK Health Centre, Department of Pediatrics, Halifax, Canada;
P393: Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.ECCO'22Year: 2022
Authors: Veyrard, P.(1);Pellet, G.(2);Laharie, D.(2);Nachury, M.(3);juillerat, P.(4);Altwegg, R.(5);Nancey, S.(6);Fumery, M.(7);Allez, M.(8);Tran minh, M.L.(9);Roblin, X.(10);
(1)CHU SAINT-ETIENNE, Gastroenterology, Saint-Priest-en-Jarez, France;(2)CHU Bordeaux, Gastroenterology, Bordeaux, France;(3)CHU Lille, Gastroenterology, Lille, France;(4)CH Bern Switzerland, Gastroenterology, Bern, Switzerland;(5)University Hospital Montpellier, Gastroenterology, montpellier, France;(6)University Hospital Lyon, Gastroenterology, lyon, France;(7)University hospital Amiens, Gastroenterology, Amiens, France;(8)Saint louis University Hospital, Gastroenterology, paris, France;(9)Saint Louis Universuty Hospital, Gastroenterology, Paris, France;(10)CHU Saint Etienne, Gastroenterology, saint priest en jarez, France;
P394: A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapyECCO'22Year: 2022
Authors: Nguyen, A.(1);Burns, M.(2);Herath, M.(3);Holt, D.(2);Gibson, P.R.(4);Milat, F.(3);Ebeling, P.(5);Moore, G.(6);
(1)Monash University- Monash Health and Alfred Health, Gastroenterology, Melbourne, Australia;(2)Monash Health, Gastroenterology, Melbourne, Australia;(3)Monash University- Monash Health and Hudson Institute of Medical Research, Endocrinology, Melbourne, Australia;(4)Monash University and Alfred Health, Gastroenterology, Melbourne, Australia;(5)Monash University and Monash Health, Endocrinology, Melbourne, Australia;(6)Monash University and Monash Health, Gastroenterology, Melbourne, Australia;
P395: Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with InfliximabECCO'22Year: 2022
Authors: Doherty, J.(1);Varley, R.(2);Dunne, C.(2);Mc Carthy, F.(1);Hartery, K.(1);Mc Kiernan , S.(1);Kevans, D.(1);
(1)St James Hospital, Gastroenterology, Dublin, Ireland;(2)St James Hospital, Department of Gastroenterology, Dublin, Ireland;
P398: Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH studyECCO'22Year: 2022
Authors: Cingolani, A.(1);Felice, C.(2);Lombardi, G.(3);Onidi, F.M.(4);Checchin, D.(5);Colucci, R.(6);Grossi, L.(7);Ferronato, A.(8);Rocchi, C.(9);Ascolani, M.(10);Binaghi, L.(4);Dore, M.F.(4);Fanini, L.(11);Bulajic, M.(9);MocciMD FRCP, G.(4);
(1)@Carlo Poma@ Hospital, Gastroenterology and Endoscopy Unit, Mantova, Italy;(2)Medicine 1- Cà Foncello University Hospital, Internal medicine, Treviso, Italy;(3)Azienda ospedaliera univeristaria integrata, Nefrology Unit, Verona, Italy;(4)Gastroenterology Unit- ARNAS G. BROTZU, Internal medicine, Cagliari, Italy;(5)@Ospedale dell'Angelo@- @San Giovanni e Paolo@ Hospital, Gastroenterology Unit, Mestre e Venezia, Italy;(6)@San Matteo degli Infermi@ Hospital, Endoscopy, Spoleto, Italy;(7)@Santo Spirito@ Hospita- @G. D'Annunzio@ University, Gastroenterology Unit, Pescara, Italy;(8)ULSS7 Pedemontana, Digestive Endoscopy Unit, Santorso, Italy;(9)@Mater Olbia@ Hospital, Gastroenterology and GI Endoscopy Unit, Olbia, Italy;(10)Gastroenterology Unit- Cà Foncello University Hospital, General Surgery, Treviso, Italy;(11)Foligno Hospital, Gastroenterology and Endoscopy Unit, Foligno, Italy;
P399: C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.ECCO'22Year: 2022
Authors: Gaspard, B.(1);Alexandre, C.(1);thibault, V.(1);Lauren, O.(2);Clotilde, D.(1);Najim, C.(1);yann, P.(1);Lefevre, J.(1);
(1)APHP St. Antoine Hospital, Department of General and Digestive Surgery, Paris, France;(2)St Vincent's University Hospital, Department of Colorectal Surgery, Dublin, Ireland;Saint-Antoine IBD Network
P400: Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH studyECCO'22Year: 2022
Authors: Buisson, A.(1);Nachury, M.(2);Reymond, M.(1);Yzet, C.(3);Wils, P.(2);Payen, L.(1);Manlay, L.(1);Pereira, B.(4);Fumery, M.(3);
(1)University Hospital Estaing, Department of Gastroenterology- IBD Unit, Clermont-Ferrand, France;(2)CHRU Lille, IBD Unit, Lille, France;(3)CHU Amiens, IBD Unit, Amiens, France;(4)CHU Clermont-Ferrand, DRCI Biostatistics Unit, Clermont-Ferrand, France;
P401: Tofacitinib tissue exposure correlates with endoscopic outcomeECCO'22Year: 2022
Authors: Verstockt., B.(1,2);Alsoud, D.(2);van Oostrom, J.(3);Smith, J.(4);Stylli, J.(4);Singh, S.(4);van Gennep, S.(3);Rahimian, P.(4);Sabino, J.(1,2);Ferrante, M.(1,2);Singh, S.(4);D'Haens, G.(1);Vermeire, S.(1,2);
(1)University Hospitals Leuven, Dpt. Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Dpt. Chronic Diseases and Metabolism, Leuven, Belgium;(3)Amsterdam UMC, Dpt. Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Progenity, Progenity, San Diego, United States;
P402: Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical programECCO'22Year: 2022
Authors: Siegmund, B.(1);Melmed, G.Y.(2);Irving, P.M.(3);Pai, A.(4);Patel, A.(4);Sheffield, J.K.(4);Caldera, F.(5);Cree, B.A.C.(6);Dubinsky, M.C.(7);
(1)Charité – Universitätsmedizin Berlin, Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles, United States;(3)Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(5)University of Wisconsin-Madison School of Medicine and Public Health, Gastroenterology, Madison, United States;(6)University of California- San Francisco Medical Center, Neurology, San Francisco, United States;(7)Mount Sinai Kravis, Gastroenterology, New York, United States;
P403: The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.ECCO'22Year: 2022
Authors: Puca, P.(1);Capobianco, I.(1);Petito, V.(1);Masi, L.(1);Fidaleo, M.(2);Del Chierico , F.(3);Palucci, I.(4);Lopetuso, L.R.(1);Laterza, L.(1);Settanni, C.R.(1);Parisio, L.(1);Bibbò, S.(1);Pugliese, D.(1);Armuzzi, A.(1);Pani, G.(5);Gasbarrini, A.(1);Scaldaferri, F.(1);
(1)Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Gastroenterology and Internal Medicine, Rome, Italy;(2)Università La Sapienza, Department of Biology and Biotechnologies @Charles Darwin@, Rome, Italy;(3)Children Hospital Bambino Gesù IRCCS, Unit of Human Microbiome, Rome, Italy;(4)Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Microbiology, Rome, Italy;(5)Catholic University of the Sacred Heart, Department of Translational Medicine, Rome, Italy;
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trialsECCO'22Year: 2022
Authors: Sedano, R.(1,2);Hogan, M.(3);McDonald, C.(4);Aswani-Omprakash, T.(5);Ma, C.(2,6);Jairath, V.(2,7);
(1)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;(2)Alimentiv Inc, Gastroenterology, London, Canada;(3)Alimentiv Inc, n/a, London, Canada;(4)Lawson Health Research Institute- Western University, n/a, London, Canada;(5)Patient Advocate, n/a, New York, United States;(6)University of Calgary, Division of Gastroenterology & Hepatology- Departments of Medicine and Community Health Sciences, Calgary, Canada;(7)Western University, Division of Gastroenterology- Department of Medicine / Department of Epidemiology and Biostatistics, London, Canada;
P405: Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank ProjectECCO'22Year: 2022
Authors: Zhao, M.(1);Larsen, L.(2);Dige, A.(3);Hvas, C.L.(3);Poulsen, A.(4);Christiansen, D.(4);Attauabi, M.(1,5);Lo, B.(1);Wewer, M.(1,6);Ovesen, P.D.(6);Petersen, A.M.(1,7);Bendtsen, F.(1);Seidelin, J.B.(5);Burisch, J.(1,4);
(1)Hvidovre University Hospital, Gastro Unit- Medical Division, Hvidovre, Denmark;(2)Aalborg University Hospital, Dept. of Gastroenterology and Hepatology, Aalborg, Denmark;(3)Aarhus University Hospital, Dept. of Hepatology and Gastroenterology, Aarhus, Denmark;(4)Bispebjerg Hospital, Digestive Disease Centre, Copenhagen, Denmark;(5)Herlev University Hospital, The Gastro Unit- Medical Division, Hvidovre, Denmark;(6)University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark;(7)Hvidovre University Hospital, Dept. of Clinical Microbiology, Hvidovre, Denmark;
